Genes shaping GLP‑1 response
- Commentators and early studies are linking specific GLP‑1 receptor and GIPR gene variants to variable drug response ( ). - Posts name variants like rs11760106 and rs9357297, and one variant is reported to explain about 10% of weight‑loss variance ( ). - Clinicians are investigating so‑called 'GLP‑1 resistance' and considering genetic insights to explain why some patients respond less well ( ).
GLP‑1 drugs work by copying gut hormones that slow stomach emptying, curb appetite and boost insulin release, but a large April 8, 2026 study found DNA differences help explain why weight loss varies from person to person. (nature.com) In that study, researchers analyzed self-reported outcomes from 27,885 people who had used glucagon-like peptide 1 medicines, including semaglutide and tirzepatide. They found a missense variant in the GLP1R gene tied to greater weight-loss efficacy, with about 0.76 kilograms of extra loss per copy of the effect allele. (nature.com) The same paper linked variation in both GLP1R and GIPR to nausea or vomiting, and the GIPR signal appeared only in people taking tirzepatide, which hits both glucose-dependent insulinotropic polypeptide and GLP-1 pathways. A Nature News & Views article published the same day said those two genes encode targets of GLP‑1-based medicines and help explain differences in efficacy and adverse effects. (nature.com; nature.com) The backdrop is wide real-world variation even before genetics enters the picture. A JAMA Network Open cohort study of 3,389 patients found mean one-year weight change of 5.1% with semaglutide versus 2.2% with liraglutide, with better results tied to obesity indication, higher dose, persistent coverage and female sex. (jamanetwork.com) That leaves clinicians sorting through patients who take the drugs as prescribed and still lose little weight or see limited glucose improvement. A Diabetes in Control article published April 20, 2026 described that pattern as reduced response to GLP‑1 therapy and said clinicians are increasingly evaluating biologic variability after checking adherence and injection technique. (diabetesincontrol.com) The genetics story is not starting from zero, but it is still early. A 2022 pharmacogenomics analysis later published in The Lancet Diabetes & Endocrinology found GLP1R and ARRB1 variants associated with differences in HbA1c reduction after six months of GLP‑1 receptor agonist treatment in 4,571 people with type 2 diabetes. (medrxiv.org) Not every candidate gene has held up. A 2024 study in Postgraduate Medicine followed 191 Greek patients with type 2 diabetes for at least six months and found no evidence that the TCF7L2 or CTRB1/2 variants it tested changed weight-loss or glucose response to GLP‑1 receptor agonists. (pubmed.ncbi.nlm.nih.gov) The new Nature paper also does not say genes determine who will or will not respond. 23andMe, whose research institute led the work, said some people on these drugs lose less than 5% of body weight while others lose more than 20%, and said its response model combined genetic, demographic and clinical factors rather than DNA alone. (mediacenter.23andme.com) For now, the clearest takeaway is narrower than the hype: common variants in the drug-target genes appear to shift odds of extra weight loss or side effects, but they explain only part of a response that still depends on dose, persistence, indication and underlying disease. (nature.com; jamanetwork.com)
